Morgan Stanley initiated coverage on shares of Genmab A/S (NASDAQ:GMAB) in a research report sent to investors on Monday, BenzingaRatingsTable reports. The brokerage issued an overweight rating on the stock.
Shares of GMAB stock opened at $19.89 on Monday. Genmab A/S has a 12 month low of $12.10 and a 12 month high of $21.45.
An institutional investor recently bought a new position in Genmab A/S stock. Parametric Portfolio Associates LLC bought a new position in shares of Genmab A/S (NASDAQ:GMAB) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 375,476 shares of the company’s stock, valued at approximately $6,937,000. Parametric Portfolio Associates LLC owned 0.29% of Genmab A/S at the end of the most recent reporting period. 0.80% of the stock is currently owned by institutional investors.
Genmab A/S Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
See Also: Short Selling
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.